Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)
tyrosine kinase inhibitor (TKI) designed to penetrate the blood brain
barrier. We report 2 cases of patients with ALK-rearrangement
non-small cell carcinoma associated with severe symptomatic CNS
metastases and poor performance status. Treatment with lorlatinib
improved their neurological condition and performance status.